Peer-influenced content. Sources you trust. No registration required. This is HCN.
Lung Cancers Today
Global phase 3 study randomized patients with platinum-refractory extensive-stage SCLC to first-in-class bispecific immunotherapy versus regional standard chemotherapy, achieving primary overall survival endpoint with consistent safety profile.
Oncology, Medical June 24th 2025
Dana-Farber Cancer Institute
Reed-Sternberg cells harbor chromosome 9p24 amplification encoding PD-1 ligand, creating therapeutic vulnerability exploited by checkpoint inhibitors with remarkable clinical responses.
Hematology/Oncology May 27th 2025
MDLinx
In mice whose immune cells that lack the ability to recognize flagellin, immune therapy induced long-term control of ovarian tumor growth in almost 80% of animals.
Obstetrics & Gynecology March 31st 2025
Northwestern Medicine
“Having achieved a complete pathologic response was the best-case scenario that we could have hoped for.”
Obstetrics & Gynecology February 11th 2025
Oncology News Central (ONC)
The phase 3 ALLELE trial demonstrated tabelecleucel’s potential with a 50.7% overall response rate and median duration of response of 23.0 months in EBV+ PTLD patients.
Hematology/Oncology February 3rd 2025
Consultant360
Combined omalizumab-OIT therapy demonstrated an impressive 50-percentage-point advantage over placebo in food challenge success rates for children with multiple food allergies.
Allergy & Immunology January 8th 2025
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS